December 9, 2022

Today And Tomorrow

Activity Overview

The 2022 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines evidence on current practice with information that might be applied in the future.

Target Audience

This activity is designed for an audience of pharmacists, physicians, and nurses.

Learning Objectives

Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.

More specifically:

Review the history of myelodysplastic syndromes.
Project future developments of myelodysplastic syndromes.
Analyze current evidence of the use of ESAs in MDS and the potential alternatives as a second line treatment.
Compare the contribution of real-world data with evidence obtained in clinical trials explaining how to address this information.
Recognize the role that inflammation has in MDS pathogenesis and the influence of aging and comorbidities on these diseases.
Identify the new molecular classification (IPSS-M) of MDS as well as the role of genetic testing in patient evaluation.
Describe the influence of anemia on quality of life and other non-hematopoietic organ function.
Discuss management of patients with MDS

Cochairs

Moshe Mittelman, MD

Stephen D. Nimer, MD

Valeria Santini, MD

Speakers

Rafael Bejar, MD, PhD

Rena Buckstein, MD, FRCPC

Jane Churpek, MD, MS

Peter C. Grayson, MD

Elizabeth Griffiths, MD

Moshe Mittelman, MD

Yasushi Miyazaki, MD

Stephen D. Nimer, MD

Sophie Park, MD, PhD

Valeria Santini, MD

Lewis R. Silverman, MD

Theo de Witte, MD, PhD

Our Supporters

Thank you to AbbVie, Astex Pharmaceuticals, Geron Corporation, Gilead, Karyopharm Therapeutics Inc, and Taiho Oncology for supporting this initiative.

Today And Tomorrow

Activity Overview

Target Audience

Learning Objectives

Cochairs

Speakers

Welcome

The History and Future of MDS

When are erythroid stimulating agents (ESA) effective and what can we offer after their failure?

Real-world data and clinical trials – does it matter?

Inflammaging, comorbidities and VEXAS syndrome in MDS pathogenesis

Molecular prognostic scoring (IPSS-M) – How does it improve patient management?

Are we ready to perform NGS in all MDS patients?

Anemia and Transfusion Dependence: Effects on quality of life and organ function

Patient Discussion – Case Study 1

Patient Discussion – Case Study 2

Our Supporters

Get in touch

Today And Tomorrow

Activity Overview

Target Audience

Learning Objectives

Cochairs

Speakers

Welcome

Welcome

The History and Future of MDSMoshe Mittelman, MD

The History and Future of MDS

When are erythroid stimulating agents (ESA) effective and what can we offer after their failure?Sophie Park, MD, PhD

When are erythroid stimulating agents (ESA) effective and what can we offer after their failure?

Real-world data and clinical trials – does it matter?Theo de Witte, MD, PhD

Real-world data and clinical trials – does it matter?

Inflammaging, comorbidities and VEXAS syndrome in MDS pathogenesisPeter C. Grayson, MD

Inflammaging, comorbidities and VEXAS syndrome in MDS pathogenesis

Molecular prognostic scoring (IPSS-M) – How does it improve patient management?Elizabeth Griffiths, MD

Molecular prognostic scoring (IPSS-M) – How does it improve patient management?

Are we ready to perform NGS in all MDS patients?Rafael Bejar, MD, PhDValeria Santini, MD

Are we ready to perform NGS in all MDS patients?

Anemia and Transfusion Dependence: Effects on quality of life and organ functionRena Buckstein, MD, FRCPC

Anemia and Transfusion Dependence: Effects on quality of life and organ function

Patient Discussion – Case Study 1Jane Churpek, MD, MSYasushi Miyazaki, MDLewis R. Silverman, MD

Patient Discussion – Case Study 1

Patient Discussion – Case Study 2Jane Churpek, MD, MSYasushi Miyazaki, MDLewis R. Silverman, MD

Patient Discussion – Case Study 2

Our Supporters

Get in touch